Researchers from the School of Biomedical Engineering & Imaging Sciences have shown that whole body magnetic resonance imaging (WBMRI) detects myeloma in more patients.
In a study published today in the European Journal of Nuclear Medicine and Molecular Imaging, researchers looked at 46 patients with suspected myeloma, a debilitating bone marrow cancer which sees 140,000 new cases each year globally.
Lead researcher Professor Vicky Goh said WBMRI is the most sensitive test for bone marrow infiltration by myeloma compared to PET/CT or CT alone as this type of imaging shows up different processes within the skeleton.
“Our results showed that imaging with WBMRI changed how patients would have been managed by their doctors in 24% of cases, where review of clinical data alone would have resulted in surveillance only.
“What this ultimately means for patients is improved outcomes from earlier treatment.”
“WBMRI resulted in a decision-to-treat in an additional 7% of patients compared with PET/CT.”
Goh said that WBMRI & PET/CT only agreed on a positive diagnosis of myeloma in 59% of patients. Just under half of the patients did not have FDG-avid disease and would have been undetected by PET alone.
She also said that the study supports national guidance for improving healthcare distributed by The National Institute for Health and Care Excellence (NICE) and that WBMRI should be performed as a first-line imaging test for suspected myeloma.
Healthcare innovators and leaders honoured at Imprivata HealthCon user group and awards ceremony
Wearable communication system may reduce digital health divide
Molecule trains the immune system to prevent cancer
Diabetes patients urged to use fitness games with caution
Urgent work needed to tackle ‘substantial’ digital health inequality
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
UK Biobank releases world’s largest single set of sequencing data
- News3 weeks ago
Why a leading healthcare CEO sees recombinant DNA as a metaphor for developing breakthrough technologies
- AI6 days ago
AI model predicts breast cancer risk without racial bias
- Medtech4 weeks ago
Surtex Instruments to unveil game-changing Infinex microsurgery instruments at MEDICA
- AI2 weeks ago
Humans make better cancer treatment decisions than AI, study finds